Mr. Robert Higgins, LMFT Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 27 Bank St, Lebanon, NH 03766 Phone: 603-448-3739 |
Dr. Lucie Bourdon Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 1 Medical Center Dr, Lebanon, NH 03756 Phone: 603-653-1732 |
Susan Davis Marriage & Family Therapist Medicare: Not Enrolled in Medicare Practice Location: 85 Mechanic St, Lebanon, NH 03766 Phone: 603-448-5610 |
News Archive
Recent legislative and regulatory actions make great strides toward establishing much needed incentives for pharmaceutical companies and others to develop and test more medications for pediatric rare diseases, including pediatric cancers, according to commentary by experts from Children's National Medical Center. The commentary appears in the January 19 issue of Science Translational Medicine.
USA Today: Doctors are limiting the number of new Medicare patients they are seeing, concerned about reimbursements pay from the federal program. "Recent surveys by national and state medical societies have found more doctors limiting Medicare patients, partly because Congress has failed to stop an automatic 21% cut in payments that doctors already regard as too low.
Cancer cells are normal cells that go awry by making bad developmental decisions during their lives. In a study involving the fruit fly equivalent of an oncogene implicated in many human leukemias, Northwestern University researchers have gained insight into how developing cells normally switch to a restricted, or specialized, state and how that process might go wrong in cancer.
Health care continues to be a top issue for Democratic and Democratic-leaning primary voters, according to recent polls. But the presidential candidates are so busy picking at the details of their opponents' plans, it's unclear whether voters are becoming educated or more confused.
DARA BioSciences, Inc. today announced that, on May 28 2010, NASDAQ notified the Company that it has regained compliance with the minimum bid price requirement as set forth in NASDAQ Listing Rule 5550(a)(2). On May 26, 2010, the Company's closing bid price was $3.58 per share, the tenth consecutive day it had been above $1 per share.
› Verified 9 days ago